Lesson plan

APINACA

APINACA (AKB48, N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) is a drug that acts as a reasonably potent agonist for the cannabinoid receptors. It is a full agonist at CB 1 with an EC 50 of 142 nM and K i of 3.24 nM (compared to the K i of Δ 9 -THC at 28.35 nM and JWH-018 at 9.62 nM), while at CB 2 it acts as a partial agonist with an EC 50 of 141 nM and K i of 1.68 nM (compared to the K i of Δ 9 -THC at 37.82 nM and JWH-018 at 8.55 nM). Its pharmacological characterization has also been reported in a discontinued patent application. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis smoking blends, along with a related compound APICA. It was deliberately being sold named after a popular girl band called AKB48. Structurally, it closely resembles cannabinoid compounds from a 2003 University of Connecticut patent, but with a simple pentyl chain on the indazole 1-position, and APINACA falls within the claims of this patent despite not being disclosed as an example.

Back to article

Article summary

APINACA (AKB48, N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide) is a drug that acts as a reasonably potent agonist for the cannabinoid receptors. It is a full agonist at CB 1 with an EC 50 of 142 nM and K i of 3.24 nM (compared to the K i of Δ 9 -THC at 28.35 nM and JWH-018 at 9.62 nM), while at CB 2 it acts as a partial agonist with an EC 50 of 141 nM and K i of 1.68 nM (compared to the K i of Δ 9 -THC at 37.82 nM and JWH-018 at 8.55 nM). Its pharmacological characterization has also been reported in a discontinued patent application. It had never previously been reported in the scientific or patent literature, and was first identified by laboratories in Japan in March 2012 as an ingredient in synthetic cannabis smoking blends, along with a related compound APICA. It was deliberately being sold named after a popular girl band called AKB48. Structurally, it closely resembles cannabinoid compounds from a 2003 University of Connecticut patent, but with a simple pentyl chain on the indazole 1-position, and APINACA falls within the claims of this patent despite not being disclosed as an example.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.